MIG Capital AG
UnverifiedMIG Capital AG is a Munich venture capital manager founded in 2004 (AIF licence since 2014) that manages the MIG Fonds series — 18 retail funds with €1.3 billion of committed capital at end-2025, distributed by HMW Kapitalanlagen AG since 2005 — investing in European deep-tech companies. Managing partners Michael Motschmann, Jürgen Kosch, Kristian Schmidt-Garve and Matthias Kromayer; landmark exits include BioNTech, immatics and Siltectra.
On This Page
Total Funds (On Fundscouter)
1
AUM
€1.3B
Founded
2004
Company Information
Investment Focus Details
Venture capital: biopharma, medtech, digital health, advanced computing, energy & environment
About MIG Capital AG
Munich’s Deep-Tech Venture House
MIG Capital AG is a Munich-based venture capital manager founded in 2004 and licensed as an AIF management company since 2014. It manages the MIG Fonds series — 18 funds with €1.3 billion of committed capital at the end of 2025, distributed to private investors by HMW Kapitalanlagen AG since 2005 — and invests in European deep-tech companies in biopharma, medtech, digital health, advanced computing and energy. Its managing partners are Michael Motschmann, Jürgen Kosch, Kristian Schmidt-Garve and Matthias Kromayer. Landmark exits include BioNTech (Nasdaq IPO 2019), immatics, Siltectra (sold to Infineon for €91 million on a €12.7 million investment), GANYMED (Astellas) and Hemovent; current holdings include AMSilk, NavVis, IQM and KONUX.
Key Figures (31 December 2025)
Committed Capital
€1.3B
Across 18 MIG funds
BioNTech Exit
€764M
On €13.1M invested
Founded
2004
Munich; AIF licence 2014
Distribution Partner
HMW
Since 2005
Focus
Deep tech
Biopharma, medtech, computing, energy
Funds on Fundscouter
1
MIG Fonds 18
Managing Partners
Michael Motschmann
Managing Partner
Jürgen Kosch
Managing Partner
Kristian Schmidt-Garve
Managing Partner
Dr. Matthias Kromayer
Managing Partner
Selected Exits
GANYMED
Sold to Astellas; €59.9m proceeds on €14.0m invested.
Siltectra
Sold to Infineon; €91.4m on €12.7m.
BioNTech IPO
Nasdaq listing; MIG’s €13.1m stake returned €763.8m.
immatics IPO
Nasdaq listing of the cancer immunotherapy company.
MIG Fonds 18 launched
Eighteenth fund starts placement with a €160m ceiling.
{M.unverifiedText}
Are you affiliated with this fund manager? Claim this profile to verify and manage it.